Drugs: Licensing

(asked on 23rd January 2023) - View Source

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, how many and what proportion of health technology appraisals conducted by NICE for follow-on indications have resulted in (a) termination, (b) a negative recommendation, (c) an optimised recommendation, (d) a positive recommendation and (e) a recommendation for use within the (i) Cancer Drugs Fund and (ii) and Innovative Medicines Fund.


Answered by
Will Quince Portrait
Will Quince
This question was answered on 2nd February 2023

Between 1 January 2017 and 31 December 2022 31% of appraisals of licence extensions by the National Institute for Health and Care Excellence (NICE) were terminated due to the company not making an evidence submission to NICE. Of the licence extensions appraised by NICE 10% were not recommended, 37% were recommended for routine commissioning, 34% were optimised recommendations and 20% were recommended or optimised for use within the Cancer Drugs Fund. No applications were recommended for the Innovative Medicines fund.

Reticulating Splines